Top > Search of International Patents > METHOD FOR DETECTION OF INFECTION BY PATHOGENIC NEISSERIA BACTERIA USING PARTIAL SUGAR CHAIN EPITOPE, AND VACCINE AGAINST THE BACTERIA

METHOD FOR DETECTION OF INFECTION BY PATHOGENIC NEISSERIA BACTERIA USING PARTIAL SUGAR CHAIN EPITOPE, AND VACCINE AGAINST THE BACTERIA meetings

Foreign code F110002561
File No. H20-034-2
Posted date Mar 23, 2011
Country WIPO
International application number 2009JP069532
International publication number WO 2010/134225
Date of international filing Nov 18, 2009
Date of international publication Nov 25, 2010
Priority data
  • P2009-122595 (May 20, 2009) JP
Title METHOD FOR DETECTION OF INFECTION BY PATHOGENIC NEISSERIA BACTERIA USING PARTIAL SUGAR CHAIN EPITOPE, AND VACCINE AGAINST THE BACTERIA meetings
Abstract An attention is focused on a branched structure of a core sugar chain of LOS produced by meningitis-inducing bacteria (Neisseria bacteria), and a tool which enables the diagnosis of meningitis by utilizing not the entire structure of the sugar chain but a partial structure of the core sugar chain is provided. In deacylated LOS, a functional group such as a phosphate group and an acetyl group expressed in the core sugar chain is also removed, and therefore deacylated LOS cannot be utilized for detecting a bacterium capable of producing the core sugar chain containing such a functional group. Thus, also provided is a diagnosis tool which is free of the concerns for those constraints. Further disclosed is a vaccine against meningitis-inducing bacteria (Neisseria bacteria), which is prepared utilizing a partial structure of the core sugar chain without carrying out deacylation. The vaccine utilizes at least one (e.g., several) partial sugar chain containing the core sugar chain, and is a vaccine which is developed based on an innovative idea so as to deal with the mutation of meningitis-inducing bacteria (Neisseria bacteria).
Scope of claims (In Japanese)
【請求項1】 対象がナイセリア属細菌および/またはヘモフィルス属細菌に感染していることを評価するための方法であって、対象から得られた試料と以下の糖鎖配列からなる糖鎖分子:
 (1)Hep-(α1-3)-Hep-(α1-5)-Kdo-(α2-4)-Kdo;
 (2)Glc-(β1-4)-Hep-(α1-3)-Hep-(3-1α)-Glc-(4-1β)-Gal;
 (3)GlcNAc-(α1-2)-Hep-(α1-3)-Hep;
 (4)Hep-(α1-2)-Hep-(α1-3)-Hep;
 (5)Gal-(β1-4)-Glc-(β1-4)-Hep[I]-(3-1α)-Hep[II];および
 (6)Hep-(α1-3)-Hep
の1種または複数を接触させ、糖鎖-抗体結合体の存在を検出することを含む方法。

【請求項2】 糖鎖分子が担体分子とコンジュゲートしているものである、請求項1に記載の方法。

【請求項3】 担体分子がヒト血清アルブミンまたはウシ血清アルブミンである、請求項2に記載の方法。

【請求項4】 ナイセリア属細菌に感染していることを評価するための方法である、請求項1~3の何れかに記載の方法。

【請求項5】 対象がナイセリア属細菌および/またはヘモフィルス属細菌に感染していることを評価するためのチップであって、固相支持体と、該固相支持体に結合した以下の糖鎖配列からなる糖鎖分子:
 (1)Hep-(α1-3)-Hep-(α1-5)-Kdo-(α2-4)-Kdo;
 (2)Glc-(β1-4)-Hep-(α1-3)-Hep-(3-1α)-Glc-(4-1β)-Gal;
 (3)GlcNAc-(α1-2)-Hep-(α1-3)-Hep;
 (4)Hep-(α1-2)-Hep-(α1-3)-Hep;
 (5)Gal-(β1-4)-Glc-(β1-4)-Hep[I]-(3-1α)-Hep[II];および
 (6)Hep-(α1-3)-Hep
の1種または複数を含むチップ。

【請求項6】 ナイセリア属細菌に感染していることを評価するためのチップである、請求項5に記載のチップ。

【請求項7】 以下の糖鎖配列からなる糖鎖分子:
 (1)Hep-(α1-3)-Hep-(α1-5)-Kdo-(α2-4)-Kdo;
 (2)Glc-(β1-4)-Hep-(α1-3)-Hep-(3-1α)-Glc-(4-1β)-Gal;
 (3)GlcNAc-(α1-2)-Hep-(α1-3)-Hep;
 (4)Hep-(α1-2)-Hep-(α1-3)-Hep;
 (5)Gal-(β1-4)-Glc-(β1-4)-Hep[I]-(3-1α)-Hep[II];および
 (6)Hep-(α1-3)-Hep
の1種または複数を含む、ナイセリア属細菌および/またはヘモフィルス属細菌に対するワクチン。

【請求項8】 ナイセリア属細菌に対するワクチンである、請求項7に記載のワクチン。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY
  • Inventor
  • YAMASAKI, Ryohei
IPC(International Patent Classification)
Specified countries AE(UTILITY MODEL),AG,AL(UTILITY MODEL),AM(PROVISIONAL PATENT)(UTILITY MODEL),AO(UTILITY MODEL),AT(UTILITY MODEL),AU,AZ(UTILITY MODEL),BA,BB,BG(UTILITY MODEL),BH(UTILITY MODEL),BR(UTILITY MODEL),BW,BY(UTILITY MODEL),BZ(UTILITY MODEL),CA,CH,CL(UTILITY MODEL),CN(UTILITY MODEL),CO(UTILITY MODEL),CR(UTILITY MODEL),CU(INVENTOR'S CERTIFICATE),CZ(UTILITY MODEL),DE(UTILITY MODEL),DK(UTILITY MODEL),DM,DO(UTILITY MODEL),DZ,EC(UTILITY MODEL),EE(UTILITY MODEL),EG(UTILITY MODEL),ES(UTILITY MODEL),FI(UTILITY MODEL),GB,GD,GE(UTILITY MODEL),GH(UTILITY CERTIFICATE),GM,GT(UTILITY MODEL),HN(UTILITY MODEL),HR(CONSENSUAL PATENT),HU(UTILITY MODEL),ID,IL,IN,IS,JP(UTILITY MODEL),KE(UTILITY MODEL),KG(UTILITY MODEL),KM,KN,KP(INVENTOR'S CERTIFICATE)(UTILITY MODEL),KR(UTILITY MODEL),KZ(PROVISIONAL PATENT)(UTILITY MODEL),LA,LC,LK,LR,LS(UTILITY MODEL),LT,LU,LY,MA,MD(UTILITY MODEL),ME,MG,MK,MN,MW,MX(UTILITY MODEL),MY(UTILITY-INNOVATION),MZ(UTILITY MODEL),NA,NG,NI(UTILITY MODEL),NO,NZ,OM(UTILITY MODEL),PE(UTILITY MODEL),PG,PH(UTILITY MODEL),PL(UTILITY MODEL),PT(UTILITY MODEL),RO,RS(PETTY PATENT),RU(UTILITY MODEL),SC,SD,SE,SG,SK(UTILITY MODEL),SL(UTILITY MODEL),SM,ST,SV(UTILITY MODEL),SY,TJ(UTILITY MODEL),TM(PROVISIONAL PATENT),TN,TR(UTILITY MODEL),TT(UTILITY CERTIFICATE),TZ,UA(UTILITY MODEL),UG(UTILITY CERTIFICATE),US,UZ(UTILITY MODEL),VC(UTILITY CERTIFICATE),VN(PATENT FOR UTILITY SOLUTION),ZA,ZM,ZW,EP(AT,BE,BG,CH,CY,CZ,DE,DK,EE,ES,FI,FR,GB,GR,HR,HU,IE,IS,IT,LT,LU,LV,MC,MK,MT,NL,NO,PL,PT,RO,SE,SI,SK,SM,TR),OA(BF(UTILITY MODEL),BJ(UTILITY MODEL),CF(UTILITY MODEL),CG(UTILITY MODEL),CI(UTILITY MODEL),CM(UTILITY MODEL),GA(UTILITY MODEL),GN(UTILITY MODEL),GQ(UTILITY MODEL),GW(UTILITY MODEL),ML(UTILITY MODEL),MR(UTILITY MODEL),NE(UTILITY MODEL),SN(UTILITY MODEL),TD(UTILITY MODEL),TG(UTILITY MODEL)),AP(BW(UTILITY MODEL),GH(UTILITY MODEL),GM(UTILITY MODEL),KE(UTILITY MODEL),LS(UTILITY MODEL),MW(UTILITY MODEL),MZ(UTILITY MODEL),NA(UTILITY MODEL),SD(UTILITY MODEL),SL(UTILITY MODEL),SZ(UTILITY MODEL),TZ(UTILITY MODEL),UG(UTILITY MODEL),ZM(UTILITY MODEL),ZW(UTILITY MODEL)),EA(AM,AZ,BY,KG,KZ,MD,RU,TJ,TM)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close